InflaRx (IFRX) Change in Account Payables (2017 - 2026)
InflaRx (IFRX) posted Change in Account Payables of -$648879.9 for Q1 2026, up 85.44% sequentially from -$4.5 million in Q4 2025, and up 79.63% YoY from -$361238.4 in Q1 2025.
InflaRx (IFRX) Change in Account Payables (2017 - 2026) Analysis & Trends
InflaRx has reported Change in Account Payables for 10 years, with the latest figure at -$648879.9 in Q1 2026.
- Quarterly Change in Account Payables rose 79.63% year-over-year to -$648879.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.1 million (down 530.8% YoY) and the FY2025 annual result came in at -$6.8 million, down 978.69% from the prior year.
- Change in Account Payables improved to -$648879.9 in Q1 2026 per IFRX's latest filing, from -$4.5 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $6.4 million in Q4 2023 and troughed at -$4.7 million in Q1 2024.
- A 5-year average of -$236878.6 and a median of -$398687.5 in 2023 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2023 and 2025: Change in Account Payables surged 357.1% in 2023, then sank 1181.08% in 2025.
- Over 5 years, Change in Account Payables stood at -$2.5 million in 2022, then soared by 357.1% to $6.4 million in 2023, then sank by 105.41% to -$347894.1 in 2024, then tumbled by 1181.08% to -$4.5 million in 2025, then surged by 85.44% to -$648879.9 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$648879.9, -$4.5 million, and -$593339.9 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 533,203.28 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -648,879.92 |
| Mar 31, 2026 | -648,879.92 |
| Dec 31, 2025 | -4.46 Mn |
| Dec 31, 2025 | -4.46 Mn |
| Sep 30, 2025 | -593,339.88 |
| Sep 30, 2025 | -593,339.88 |
| Jun 30, 2025 | 1.55 Mn |
| Jun 30, 2025 | 1.55 Mn |
| Mar 31, 2025 | -3.18 Mn |
| Mar 31, 2025 | -3.18 Mn |
| Dec 31, 2024 | -347,894.06 |
| Dec 31, 2024 | -347,894.06 |
| Sep 30, 2024 | 3.49 Mn |
| Sep 30, 2024 | 3.49 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | -4.74 Mn |
| Mar 31, 2024 | -4.74 Mn |
| Dec 31, 2023 | 6.43 Mn |
| Dec 31, 2023 | 6.43 Mn |